Guojin Securities Research Report pointed out that special insulin collection projects have been launched one after another, and the market response has been enthusiastic. Overall, the market's expectations for collection are becoming more stable and mature, and excessive panic has improved markedly. Therefore, the completion of harvesting in 2024 will be an important window of investment opportunity. It is recommended to focus on opportunities such as clear collection of in vitro diagnostic collection, clear collection of biopharmaceuticals, and clearance of proprietary Chinese medicines.
国金证券：关注体外诊断集采出清、中成药集采出清等机会
Guojin Securities: Focus on opportunities such as in vitro diagnostic collection clean-up and proprietary Chinese medicine collection
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.